INS and osteosarcoma: Much of the concern about insulin glargine stemmed from in vitro experiments exposing human osteosarcoma cells (Saos/B10) to insulin glargine which revealed a 6.5-fold higher affinity for the IGF-1 receptor and an 8-fold greater mitogenic action in comparison to insulin [31].